Celyad Receives the First US Patent Covering a Method of Producing Allogeneic TCR-Deficient CAR T-Cells
March 02, 2016 01:00 ET
|
Celyad
MONT-SAINT-GUIBERT, Belgium, March 02, 2016 (GLOBE NEWSWIRE) -- Celyad (Euronext Brussels:CYAD) (Paris:CYAD) (NASDAQ:CYAD), a leader in the discovery and development of engineered cell therapies,...
Celyad to Host an Immuno-Oncology R&D Analyst Day on March 24th in New York City
February 29, 2016 01:00 ET
|
Celyad
Expert panel to present on next generation T-Cell therapy using the natural killer cell receptor NKG2DCelyad to present its immune-oncology portfolio with emphasis on the natural killer receptor...
Celyad Successfully Completes Safety Follow-Up of the Second Dose Level of Patients in Its NKR-2 Trial and Enrolls First Patient in the Third Dose Level
February 25, 2016 01:00 ET
|
Celyad
The trial is a dose escalation study evaluating safety and feasibility of T-cell Natural Killer Receptor NKG2D in patients with acute myeloid leukemia or multiple myeloma.No dose limiting toxicity...
Prof. William Wijns Appointed to Chair the Scientific Committee That Will Oversee the CHART-1 Data Analysis and Dissemination Plan.
February 08, 2016 01:00 ET
|
Celyad
MONT-SAINT-GUIBERT, Belgium, Feb. 08, 2016 (GLOBE NEWSWIRE) -- Celyad (Euronext Brussels:CYAD) (Paris:CYAD) (NASDAQ:CYAD), a leader in the discovery and development of engineered cell therapies,...
Celyad Appoints Dr. Richard Mountfield as Vice-President of Global Regulatory Affairs
February 03, 2016 01:00 ET
|
Celyad
MONT-SAINT-GUIBERT, Belgium, Feb. 03, 2016 (GLOBE NEWSWIRE) -- Celyad (Euronext Brussels:CYAD) (Paris:CYAD) (NASDAQ:CYAD), a leader in the discovery and development of engineered cell therapies,...
Celyad Announces 2016 Financial Calendar
January 20, 2016 01:00 ET
|
Celyad
MONT-SAINT-GUIBERT, Belgium, Jan. 20, 2016 (GLOBE NEWSWIRE) -- Celyad (Euronext Brussels:CYAD) (Paris:CYAD) (NASDAQ:CYAD), a leader in the discovery and development of engineered cell therapies,...
Celyad Completes 30-Day Safety Follow-Up of First Patient of Second Cohort in NKG2D CAR T-Cell Phase I Trial
January 05, 2016 01:00 ET
|
Celyad
No dose limiting toxicity related to the investigational treatment reported at 30 days post treatment of the first patient of the second dose-level;The trial is a dose escalation study evaluating...
Celyad to Address US Institutional Investors in January at J.P. Morgan Healthcare Conference
December 23, 2015 01:00 ET
|
Celyad
MONT-SAINT-GUIBERT, Belgium, Dec. 23, 2015 (GLOBE NEWSWIRE) -- Celyad (Euronext Brussels:CYAD) (Paris:CYAD) (NASDAQ:CYAD), a leader in the discovery and development of engineered cell therapies,...
Celyad Receives Clearance From the US FDA on Its CHART-2 Phase III IND
December 21, 2015 01:00 ET
|
Celyad
MONT-SAINT-GUIBERT, Belgium, Dec. 21, 2015 (GLOBE NEWSWIRE) -- Celyad (Euronext Brussels:CYAD) (Paris:CYAD) (NASDAQ:CYAD), a leader in the discovery and development of engineered cell therapies,...
Celyad Announces the Publication of Its CHART-1 Trial Design Methods Paper in the European Journal of Heart Failure
December 16, 2015 01:00 ET
|
Celyad
MONT-SAINT-GUIBERT, Belgium, Dec. 16, 2015 (GLOBE NEWSWIRE) -- Celyad (Euronext Brussels and Paris, and NASDAQ:CYAD), a leader in the discovery and development of engineered cell therapies, with...